.25 glp 1 Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead How GLP-1 Medications Reduce Heart

We adjust the ramp to balance comfort with progress

Here are the most common worries, and how we address them: *In a 68- and 72-week clinical trial studying Wegovy (2.4 mg) and Zepbound (15 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)

Currently, there are four main treatments propelling this market forward: Ozempic and Wegovy (semaglutide: a GLP-1 agonist, developed by Novo Nordisk) Mounjaro and Zepbound (tirzepatide: a dual agonist targeting both GLP-1 and GIP (Gastric inhibitory polypeptide) receptors, developed by Eli Lilly) These medications are administered subcutaneously with the assistance of injection pens

Aron has recommended such medications in your weight loss program, they are provided free of charge during your follow up visit